Business context and reporting period
The supplied filing is PerkinElmer, Inc.’s Form 10-K for the 52-week fiscal year ended January 2, 2011; it is not a standalone quarterly filing. The filing includes unaudited fourth-quarter results. PerkinElmer operated through Human Health and Environmental Health, selling diagnostics, research, analytical instrumentation, and laboratory services globally.
Entity mismatch: Request metadata names Revvity, Inc., while the filing identifies PerkinElmer, Inc. and ticker PKI. Verify the intended issuer before relying on this summary.
Financial results and key metrics
Amounts below are in U.S. dollars. Fiscal-year comparisons are against the year ended January 3, 2010.
| Metric | FY 2010 | FY 2009 | Change / context |
|---|---|---|---|
| Continuing-operations sales | $1,704.3 million | $1,550.8 million | Up 10%; acquisitions contributed about 2%, with no net currency impact |
| Gross profit / margin | $758.6 million / 44.5% | $699.0 million / 45.1% | Margin down 0.6 percentage points, mainly from product mix |
| Operating income / margin | $153.6 million / 9.0% | $121.9 million / 7.9% | Operating margin improved about 1.2 percentage points |
| Continuing-operations net income | $135.9 million | $74.3 million | Effective tax rate was 16.1%, versus 30.0% |
| Net income, including discontinued operations | $383.9 million | $85.6 million | FY 2010 includes a large divestiture gain |
| Continuing-operations diluted EPS | $1.15 | $0.64 | Net diluted EPS was $3.25, including $2.10 from discontinued operations |
Fourth quarter: Sales were $470.0 million versus $428.5 million a year earlier; operating income from continuing operations was $48.3 million versus $49.6 million. Net income was $288.5 million, including the IDS divestiture gain; diluted EPS was $2.46, versus $0.34 in Q4 2009. The fourth-quarter net-income increase therefore does not represent recurring operating performance.
- Segments: Human Health sales were $796.3 million, up 9%, with operating income of $96.5 million, up 20%. Environmental Health sales were $908.0 million, up 11%, with operating income of $92.3 million, up 22%.
- Cash flow: Continuing-operations operating cash flow was $167.2 million, up from $127.8 million. Continuing-operations capital expenditures were $33.6 million; operating cash flow less capital expenditures was approximately $133.6 million. Continuing investing activities used $174.1 million, including acquisition spending.
- Liquidity: Cash and equivalents were $420.1 million, versus $179.7 million a year earlier. Current assets were $1,085.0 million and current liabilities $515.2 million. The company reported $362.0 million available on its revolving facility.
- Debt: Debt totaled approximately $426.3 million: $274.0 million drawn on the revolving facility, $150.0 million of 6% senior notes due 2015, and $2.3 million of other short-term debt. The $274.0 million revolving balance matures in 2012. The company reported compliance with debt covenants.
- Other measures: R&D expense was $95.4 million, or 5.6% of sales. Restructuring and lease charges were $19.0 million. Total assets were $3.21 billion and stockholders’ equity was $1.93 billion.
Material changes versus the prior comparable period
- After sales fell 7% in FY 2009, continuing-operations sales rose 10% in FY 2010 as end markets recovered. Human Health benefited from medical imaging demand and academic research; Environmental Health grew in OneSource services, testing products, and traditional chemical markets.
- Gross margin declined despite sales growth, as the mix shifted toward lower-margin offerings. Higher volume and cost containment helped lift operating income and margin.
- Cash from continuing operations increased, while working capital consumed $32.9 million, including higher receivables and inventory. Debt declined from $558.3 million to $426.3 million.
- The IDS business was sold in November 2010 for approximately $500 million, or $482 million net of acquired cash payments, generating a $315.3 million pretax gain. Photoflash was also sold, generating a $4.4 million pretax gain.
- FY 2010 included acquisitions of Signature Genomic, VisEn, and the remaining interest in the ICPMS joint venture. A February 2011 chemagen acquisition, for approximately $35 million plus potential additional consideration, occurred after year-end.
Outlook, commentary, risks, and unusual items
- Management described improving but uneven and uncertain global conditions and expected to continue investing in R&D in FY 2011. It expected capital expenditures to be similar to FY 2010. The filing does not provide clear numerical revenue or EPS guidance.
- Management intended to reinvest proceeds from the IDS sale in Human Health and Environmental Health. It planned to repatriate $250 million of foreign cash and recorded $65.8 million of related tax expense in discontinued operations; it expected to use tax attributes so cash taxes on repatriation would be minimal.
- The $25.6 million pretax gain from remeasuring the previously held ICPMS joint-venture interest reduced reported interest and other expense. The IDS and Photoflash gains and related discontinued-operations tax expense also materially affect comparisons of net income.
- Key risks include uncertain customer and government funding, economic and capital-spending cycles, foreign exchange and international exposure, competition and timely product development, acquisition integration, limited-source suppliers, regulatory compliance, intellectual-property litigation, and debt covenants/refinancing needs.
- The company accrued $6.0 million for known environmental matters and said additional losses were possible, though not expected to be materially different from recorded amounts. The Enzo patent and related claims case remained stayed; management believed it had meritorious defenses and did not expect a material financial-statement impact.
- Management and the independent auditor concluded that disclosure controls and internal control over financial reporting were effective; the financial-statement audit opinion was unqualified.
Important facts for investors to verify
- Confirm the intended issuer: the request says Revvity, Inc., but this filing is for PerkinElmer, Inc. Verify the correct company and filing.
- Separate recurring continuing-operations earnings from the $315.3 million pretax IDS gain, other disposal gains, and discontinued-operations tax charges.
- Review the sustainability of segment growth and margins, particularly the lower gross-margin product mix and the contribution from acquisitions.
- Assess liquidity and the 2012 revolving-facility maturity, covenant terms, and the company’s stated reliance on external sources for debt repayment and larger acquisitions.
- Check subsequent developments, including the planned $250 million repatriation, post-year-end share repurchases, and the chemagen acquisition and contingent consideration.